These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36843558)

  • 1. Use of optimal medical therapy in patients with diabetes and atherosclerotic cardiovascular disease: Insights from a prospective longitudinal cohort study.
    Arnold SV; de Lemos JA; Zheng L; Rosenson RS; Ballantyne CM; Alam S; Bhatt DL; Cannon CP; Kosiborod M;
    Diabetes Obes Metab; 2023 Jun; 25(6):1750-1757. PubMed ID: 36843558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.
    Nelson AJ; O'Brien EC; Kaltenbach LA; Green JB; Lopes RD; Morse CG; Al-Khalidi HR; Aroda VR; Cavender MA; Gaynor T; Kirk JK; Lingvay I; Magwire ML; McGuire DK; Pak J; Pop-Busui R; Richardson CR; Senyucel C; Kelsey MD; Pagidipati NJ; Granger CB
    JAMA Netw Open; 2022 Feb; 5(2):e2148030. PubMed ID: 35175345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
    Pagidipati NJ; Nelson AJ; Kaltenbach LA; Leyva M; McGuire DK; Pop-Busui R; Cavender MA; Aroda VR; Magwire ML; Richardson CR; Lingvay I; Kirk JK; Al-Khalidi HR; Webb L; Gaynor T; Pak J; Senyucel C; Lopes RD; Green JB; Granger CB;
    JAMA; 2023 Apr; 329(15):1261-1270. PubMed ID: 36877177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
    Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
    JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
    Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Yazdi D; Elliott-Davey M; Mues KE; Bhatt DL; Kosiborod MN;
    Am Heart J; 2020 Jan; 219():70-77. PubMed ID: 31726422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
    Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
    Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    Circulation; 2019 Jun; 139(25):e1144-e1161. PubMed ID: 30586775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in high-intensity statin use and low-density lipoprotein cholesterol control among patients enrolled in a clinical pharmacy cardiac risk service.
    Lamprecht DG; Shaw PB; King JB; Hogan KN; Olson KL
    J Clin Lipidol; 2018; 12(4):999-1007. PubMed ID: 29803357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockers for Atherosclerosis Prevention: a Missed Opportunity?
    Vrablik M; Corsini A; Tůmová E
    Curr Atheroscler Rep; 2022 Mar; 24(3):161-169. PubMed ID: 35174437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Wilson PWF; Polonsky TS; Miedema MD; Khera A; Kosinski AS; Kuvin JT
    J Am Coll Cardiol; 2019 Jun; 73(24):3210-3227. PubMed ID: 30423394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.
    Morieri ML; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2020 Nov; 19(1):190. PubMed ID: 33172454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER.
    Arnold SV; Tang F; Cooper A; Chen H; Gomes MB; Rathmann W; Shimomura I; Vora J; Watada H; Khunti K; Kosiborod M
    BMC Endocr Disord; 2022 Apr; 22(1):111. PubMed ID: 35473607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management.
    Mancini GBJ; Gupta M; Tsigoulis M; Cannon CP; Genest J; Ray KK; Santos RD; Watts GF; Raggi P
    Atherosclerosis; 2017 Aug; 263():112-118. PubMed ID: 28623740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.